Marina del Rey

Researchers are conducting a non-interventional, observational study to collect real-world data on the use of an autologous hair follicle derived secretome topical cosmetic product as an adjunct following various medical aesthetic procedures. The study focuses on adults aged 18 to 60 undergoing these procedures and aims to better understand post-procedural symptoms and recovery. Participants plan to use the Acorn Autologous Hair Follicle Secretome cosmetic product after medical aesthetic treatments such as laser resurfacing, microneedling, and other related procedures. The study includes individuals with different Fitzpatrick skin types and those receiving hair procedures with stable hair loss medication use. Some specific hair and scalp treatments are closed to enrollment. During the study, participants will be observed for post-procedure symptoms and will complete downtime questionnaires for 1 to 7 days following their procedures. Researchers will gather data on recovery and any side effects experienced. The study is open-label, multi-site, and will follow participants over time to monitor outcomes related to the product use and aesthetic treatments.

Researchers are evaluating the effect of fisetin, a natural substance found in strawberries and other foods, on physical function in postmenopausal women who have received chemotherapy for stage I-III breast cancer. This phase II trial focuses on whether fisetin can help improve physical function by eliminating senescent cells that accumulate after chemotherapy, which may cause inflammation and damage to healthy cells. Participants are randomly assigned to receive either fisetin or a placebo orally on days 1, 2, and 3, repeated every two weeks for up to eight weeks, unless disease progression or unacceptable side effects occur. Blood samples are collected throughout the trial to study various biological markers. After treatment, participants are followed yearly for up to three years to monitor long-term outcomes. During the study, participants undergo assessments of physical function such as the 6-minute walk distance, grip strength, and frailty measures. Researchers also evaluate fatigue, neuropathy, cognitive function, quality of life, sleep, anxiety, and depression. Safety and adherence to the study treatment are monitored through patient reports and diaries. The study tracks recurrence-free survival and overall survival over three years, aiming to better understand how fisetin affects health after chemotherapy.

Researchers are evaluating how fisetin, a natural substance found in strawberries and available as a supplement, combined with exercise, may help prevent frailty in postmenopausal breast cancer survivors who have completed chemotherapy. Frailty is a concern because aging cells called senescent cells can cause inflammation and harm healthy tissues. This phase II trial aims to see if fisetin and exercise improve physical function and other health measures in this group. Participants are randomly assigned to one of four groups fisetin with exercise, fisetin with a physical activity handout, placebo with exercise, or placebo with a physical activity handout. Fisetin or placebo is taken orally on days 1-3 of every 14-day cycle for 8 cycles, while exercise groups receive supervised aerobic and resistance training three times a week for 16 weeks. Blood samples are collected during the study. Participants are assessed for changes in physical function using tests like the 6-minute walk distance, grip strength, fatigue levels, neuropathy symptoms, cognition, and quality of life from baseline to day 120. Safety and adherence to treatments are monitored, and participants are followed up at days 120 and 180, then annually for up to three years to track survival and recurrence outcomes.

Researchers are investigating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone for men with metastatic castration-sensitive prostate cancer mCSPC who have not previously received androgen receptor pathway inhibitors ARPI or chemotherapy in this setting. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study aims to compare these treatments to understand if the combination improves outcomes for participants. Participants will be randomly assigned to one of two groups one group will receive mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, while the other group will receive a placebo plus enzalutamide 160 mg once daily. The study includes several phases Screening, Randomization, Treatment, Safety Follow-up, and Long-Term Follow-up. Prior short-term androgen-deprivation therapy ADT of up to 3 months is allowed if there is no disease progression before starting the study. During the study, participants will have regular assessments including radiographic scans to monitor disease progression, laboratory tests, patient-reported questionnaires on pain and quality of life, and blood samples to evaluate tumor DNA and drug levels. The main measure is radiographic progression-free survival tracked for up to about 4 years. Safety outcomes and overall survival will also be monitored for several years. The total participation may last up to nearly 9 years, including long-term follow-up to understand treatment effects and safety over time.